NSE: KRONOX · BSE: 544187 · ISIN INE0ATZ01017
Kronox Lab Sciences Limited stock analysis
Kronox Lab Sciences Limited ranks #482 in the TickerSutra evidence-ranked universe with a score of 64/100 and 89% data confidence. The latest captured fundamentals show ROCE of 36.0%, quarterly sales growth of 16.9% and quarterly profit growth of 16.2%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 36%
- Low debt/equity of 0.02×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹82cr | ₹20cr | ₹14cr | 24.0% |
| 2023 | ₹96cr | ₹22cr | ₹16cr | 23.0% |
| 2024 | ₹90cr | ₹28cr | ₹21cr | 32.0% |
| 2025 | ₹100cr | ₹33cr | ₹25cr | 33.0% |
| 2026 | ₹101cr | ₹34cr | ₹28cr | 34.0% |
| TTM | ₹105cr | ₹35cr | ₹29cr | 33.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Kronox Lab Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on September 29, 2026.
RoutineDisclosure under SEBI Takeover RegulationsNSE · 29 Sept 2026Indo Borax & chemicals Ltd has Submitted to the Exchange a copy of Disclosure Under Regulation 18(6) of the SEBI (SAST) Regulations, 2011.
RoutineTrading WindowBSE · 29 Sept 2026Kronox Lab Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
MANAGEMENT COMMENTARY
Signals from filed documents
Projections indicate India is on track to officially overtake both Japan and the UK in nominal value by 2027 to become the 4th, and eventually 3rd, largest economy worldwide. 56 FINANCIAL STATEMENTSCORPORATE OVERVIEW STATUTORY REPORTS REPORT ON CORPORATE GOVERNANCE Compliance of the Corporate Governance Code is given below which forms part of the Board’s Report for the year 2025-26: Company’s Philosophy on Corporate
10/- each for the financial year ended March 31, 2026. The dividend, if approved by the members in the ensuing Annual General Meeting, would absorb Rs. 185.40 Lakhs out of the distributable profits available subject to TDS as applicable Dividend Distribution Policy of the Company is available at Company’s website at https://www.kronoxlabsciences.com/inves tors/corporate-policies/ 3.
The results are available on the website of the Company. There were no presentations made to the institutional investors or analysts during the financial year. 71 Annual Report / 2025-26 Foreign Exchange Risk The Company has a policy in place to protect its interests from risks arising out of market volatility.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…